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Background & objectives: Wilson disease (WD) is an autosomal recessive disorder caused by defects in
ATP7B gene located in chromosome 13q14, and manifested as hepatolenticular degeneration as a
result of accumulation of copper. No information on the mutation in the ATP7B gene and haplotypes
using linked markers is available for WD patients in India. Hence, the present study was undetaken
to identify, by a PCR-based molecular diagnostic test, presymptomatic siblings of WD affected individuals
in families with multiple offspring.
Methods: Genomic DNA was prepared from the peripheral blood of the patients, siblings and his/her
first degree relatives. The repeat-markers flanking WD locus  were amplified by PCR using fluorescent
labeled primers. Amplified   DNA fragments were analyzed by polyacrylamide gel electrophoresis in
ABI 377 DNA sequencing system. Genotypes of the samples were determined using Genescan software.
Haplotypes were determined based on segregation of the alleles in the families under study.
Results: Among 15 WD affected families with multiple children, 4 cases were identified where younger
siblings shared same genotype as the patient at all three markers analyzed. Further, eight different
haplotypes were detected in the four patients.
Interpretation & conclusion: The siblings of the WD patients carrying the same genotype at the markers
linked to WD locus were presymptomatically diagnosed individuals. Presence of eight different
haplotypes in the four patients suggested mutational heterogeneity at the WD locus. The test helps
clinicians for therapeutic intervention in suspect WD cases by copper chelating agents prior to
manifestation of overt clinical symptoms.
Key words ATP7B - genotype - haplotype - microsatellite - Wilson disease
Indian J Med Res 118, November 2003, pp 208-214
Wilson disease (WD) is a genetic disorder, which
manifests as hepatolenticular degeneration as a result of
accumulation of copper in the brain, liver, kidney and cornea
due to its deranged biliary excretion1. In 1912, a WD was
described as a familial syndrome of progressive lenticular
degeneration associated with cirrhosis of the liver2. The
etiological role of copper in the pathogenesis of WD was
recognized much later in 19483, and the autosomal recessive
mode of inheritance was established in 19534. In India WD
was first reported in 19635. Though the manifestations of
WD appear at a median age of 12 to 23 yr, the biochemical
defects are present from the birth. The diagnosis is usually
based on clinical and biochemical observations. Traditional
screening includes slit-lamp examination of the eyes and
208
*Present address : Tufts University, Boston, Massachusetts, USA
GUPTA et al : PRESYMPTOMATIC DIAGNOSIS OF WILSON DISEASE                           209               
serum ceruloplasmin level measurement. As the 
disease does not usually manifest earlier than the 
second decade of life, the patients usually go 
untreated till they show the symptoms though it can 
be thwarted by the use of chelating agents such as 
penicillamine and zinc acetate6. Recent reviews7-10 
describe the advances made in the molecular genetic 
studies in WD, which have brought new hope to the 
management of the disease. Till date, genetic 
analysis is the most successful method for 
presymptomatic identification of the patients 11,12. 
Progress in diagnosis of  WD has  been made by 
locating the causal gene (ATP7B) on the long arm of 
chromosome 13, enabling the use of flanking 
microsatellite markers to study the transmission of 
WD in siblings of affected individuals by linkage 
analysis 13,14. Specifically, three highly 
polymorphic dinucleotide-repeat markers D13S314 
(CA repeat), D13S133 (GA 14GT17 repeat) and 
D13S316 (CA repeat) are used for this purpose. The 
reported numbers of alleles are 12, 17, and 9 in the  
size-ranges 137-163 for D13S314, 134-187 for 
D13S133 and 138-154 for D13S316 loci, 
respectively14. Presence of mutation spanning  the 
entire length of the ATP7B gene and the large size 
(80 kb) of the gene make mutation screening an 
arduous and time consuming  effort. 
No information regarding the mutation in the 
ATP7B gene and haplotypes using linked markers is 
available for WD patients in India. As part of a 
broader study to identify prevalent mutations among 
Indian WD patients based on haplotype analyses 
and mutation screening, we have been genotyping 
the parents and all the siblings of WD patients. Here 
we report identification, by a PCR-based molecular 
diagnostic technique, of  younger presymptomatic 
siblings of  WD patients in the affected families.  
Material & Methods  
Clinical diagnosis of index cases: Wilson disease 
patients mostly with neurological problems were 
examined at the Bangur Institute of Neurology, 
Kolkata. Diagnosis was made according to the 
Sternlieb's criteria 1 which include overt 
neurological disorders, low serum ceruloplasmin 
(<20 mg/dl), 24 h urine copper excretion (>100µg) 
and Kayser-Fleischer (K-F) ring in the cornea by 
slit-lamp examination. Other relevant tests were 
conducted according to the need of the patients and 
for the diagnosis of the disease.  
Collection of blood samples and genomic DNA 
preparation: About 5 ml peripheral blood samples 
were collected in EDTA vials from 136 individuals 
who belonged to 38 WD affected families with one 
patient in each family 
 
Among 38 families, 23 had single child per family, and 
15 had multiple children (2-4 siblings). Prior to sample 
collection, written consent was taken from all participants 
in this study. The internal review committee on research 
using human subject cleared the protocol of this study. 
The blood samples from the patients and their family 
members were collected from 1998 onwards and the 
molecular studies were undertaken from 1999. Genomic 
DNA was prepared from fresh whole blood using the 
conventional phenol-chloroform method15 followed by 
ethanol precipitation and the DNA was dissolved in TE 
buffer (10 mM Tris -HCl, 1mM EDTA, pH 8.0).  
Polymerase chain reaction (PCR) and genotyping: PCR 
was carried out in a total volume of  25.0 µl containing 
100 ng genomic DNA, 0.4 µM of each primer 
(Invitrogen, Carlsbad, California), 0.2 mM of each dNTP 
(Invitrogen, Carlsbed, California), 2.5 mM of MgCl2 
(Sigma-Aldrich Fine Chemicals, St. Louis, Missouri) and 
0.5 unit of Taq polymerase (Invitrogen, Carlsbad, 
California) in a thermocycler (GeneAmp -9700, Applied 
Biosystems, California, USA). Dinucleotide-repeats 
(D13S133, 
 
Fig. 1. WD locus map and chromatogram for typical 
marker analysis. Panel A, location of markers used for 
genotyping relative to WD  locus. Among four markers 
shown, D13S301 could not be amplified consistently 
despite multiple attempts under various conditions. 
Marker D13S314 is located on the centromeric (Cen) 
end, and markers D13S133 and D13S316 on the 
telomeric (Tel) end relative to location WD locus on the 
chromosome 13. Panel B , a typical chromatogram 
obtained for dinucleotide repeat marker is shown with the 
size of the alleles. Smaller peaks preceding both the 
alleles are due to 'stutter bands' typically seen for PCR-
amplified dinucleotide repeat markers irrespective of the 
method of analysis using. The two peaks represent allele 
sizes of 163 and 185 base pairs bp.  
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Clinical history of the patients in families where
presymptomatic  individuals were diagnosed:
A young female (18 yr) student (Fig. 2A,II-1) was
presented in April 1999 with complaint of yellow
discolouration of  the eyes and urine, and swelling of
legs and abdomen for the last 3 months. She had a past
history of tuberculosis adenitis, which was confirmed by
fine needle aspiration cytology, and was on antitubercular
drugs since October 1997 but had developed drug
induced jaundice during the treatment. On examination
in 1999, she was diagnosed to have hepatitis with ascitis
and K-F ring in her eyes. Neurological examination was
uneventful. Laboratory investigations revealed a picture
of hepatitis and copper overload confirming it to be due
to WD. The patient improved with penicillamine and later
put on oral zinc therapy.
A 10 yr old boy (Fig. 2B II-1) was presented in the
clinic in February 2002 with behavioural abnormalities
like aloofness, apathy, drooling of saliva and sustained
abnormal posturing of  limbs as well for the past 3 months.
There was an acceleration of the disease process for
the past 2 months from when dysarthria, dysphagia,
D13S314 and D13S316) flanking WD locus (Fig.1,
panel A) were amplified using fluorescent labeled primers
as described previously13,14. The sequence of the primers
used and the fluorescent labels are shown in Table I.
Amplified PCR products were separated by 6 per cent
native polyacrylamide gel analysis in ABI 377 DNA
sequencing system using Genescan - 500 TAMRA size
Standard (Applied Biosystems, California, USA). The size
of the alleles represent the length of the amplified DNA
fragment for each marker locus in bp as determined by
the Genescan software (Applied Biosystems, California,
USA). The output chromatogram, typical for dinucleotide
repeat markers, is illustrated in Fig. 1 (panel B).
Results & Discussion
All 38 families included in this study had one child
affected with WD but neither of the parents in any family
was affected with the disease. Fifteen of the 38 couples
had multiple offspring, who were genotyped using
markers flanking WD locus for molecular diagnosis of
presymptomatic children. Genotypes of all the children
of these 15 families are shown in Table II.
Table I . Primers used for amplification of microsatellite markers flanking WD locus
   Locus Nature of Sequence of primers (5' to3')
   name repeat Forward* Reverse
D13S316 CA repeat Fam-GCA GCA ATG CTT TGT GCA TAA TGT TTC CCA CCA ATC TTA CCG
D13S133 (GA)14 (GT)17 Fam-GCT AGG ACT ACA GGT GCA AAC C GGC AAC ATA GGG AAA CCC TAGC
D13S314 CA repeat Tet-GAG TGG AGG AGG AGA AAA GA GTG TGA CTG GAT GGA TGT GA
*forward primers were fluorescent tagged as indicated
Table II . Families affected with Wilson disease
   Family Child(ren) per Genotypes of children
     no. family (+,+) (+,WD) (WD,WD)
1 2 - - 1+1*
2-7 2 - 1 1
8 2 1 - 1
9 2 nd nd 1
10-11 3 0 2 1
12 3 1 0 1+1*
13 3 2 0 1
14 3 0 1 1+1*
15 4 0 2 1+1*
nd, not determined due to identified cross over between D13S314 and D13S133 markers; (+,+), homozygous normal; (+,WD), heterozygous
who are phenotypically normal carriers; (WD,WD), homozygous for mutation who are affected with the disease excepting four individuals
in four families marked with asterisk. In 23 out of 38 families, the proband did not have any sib, hence not included in the Table.
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choking, nasal regurgitation and abnormal straightening 
of the legs and twisting of the hands started resulting in 
rapid incapacitation of the patient to carry out his daily 
activities. KF ring was detected in his eyes. His blood 
tests revealed a decrease of serum ceruloplasmin (2.5 
mg%) and increased 24 h urinary copper excretion (160 
µg) indicating copper over-load. Magnetic resonance 
imaging (MRI) suggested WD. 
 
Another 14 yr old boy (Fig. 2C, II-1) started behavioural 
abnormality from mid 1998 in the form of sense of fear, 
restlessness, incoherent speech, destructive attitude, 
running amo k and visual hallucination. He was brought to 
the clinic in October 2001 and put on antipsychotic 
medication without any relief. Gradually,  
  the patient developed dystonic posturing of limbs and 
trunks, had difficulty in walking, dysarthria, drooling of 
saliva with tremor of limbs. Later, the patient developed 
focal convulsion. He did not have past history of jaundice 
or any family history of such a presentation. Examination 
revealed that the patient was anarthric, generalized 
cogwheel rigidity with dystonic posturing without any 
pyramidal sign. Cerebellar functions were difficult to 
assess during admission but later cerebellar test revealed 
abnormality in coordination. Ophthalmic examination 
revealed K-F ring. Serum ceruloplasmin levels were 3.0 
mg%; 24 h urine copper 320 µg; liver function tests and 
routine haematological examinations were under normal 
limits. MRI suggested WD.  
Fig. 2. Genotype and haplotype analysis in Wilson disease affected families. Squares and circles represent males and 
females, respectively. The probands and his/her clinically normal siblings sharing the same genotypes are denoted by 
shaded and stripped symbols, respectively while all other clinically normal individuals in the family (both homozygous 
normal and WD-carrier) are shown by open symbols. In each pedigree, unique numbers identifies all individuals in the 
generation (I or II) they belong to, and their ages are also shown in each case. Haplotypes as determined from the 
genotypes of 3 marker loci (D13S1316, D13S133 and D13S314) are shown for all the individuals included in the study. 
Unlike other di-nucleotide repeats, even and odd size alleles observed for D13S133 (e.g. panel A, I-1; panel B, I-1 & I-2) 
has been previously reported14 and might result from presence of, yet uncharacterized, single nucleotide insertion in the 
region amplified by PCR.   
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A 22 yr old male (Fig. 2D, II-1)  complained of
dribbling of saliva, sleep disturbance, inability to move
limbs fluently, trembling of  the extremities and difficulty
of swallowing for the past 18 months when he was
presented to the clinic in June 1999. He also gave the
history of cognitive decline. Before that he was entirely
well and his development as described by his parents
was normal. On examination he showed evidence of
slurred speech, tremor, incoordination in movements,
spastic - ataxic features with presence of K-F ring in
the eye. Jerks were brisk and planter flexor. Biochemical
examination showed serum ceruloplasmin 8 mg per cent,
serum glucose and urea were in normal range, urinary
copper  excretion for 24 h was 160 µg indicating copper
overload. Routine CSF examination was non-
contributory. The patient was treated  with penicillamine.
Haplotype analysis: All the three CA-repeat markers
(D13S314, D13S133 and D13S316) were informative in
the families included in this study. The total number of
alleles identified for D13S314, D13S133 and D13S316
markers were 11, 18 and 9, respectively. These values
are comparable to the reported numbers of alleles, that
is, 12, 17, and 9 in the size-ranges 137-163 for D13S314,
134-187 for D13S133 and 138-154 for  D13S316 loci,
respectively14. Genotypes were determined at each of
the three dinucleotide repeat markers for each member
of the core family (both parents and siblings) of the index
patients. In each case the haplotype was constructed
using the genotype data, following the Mendelian pattern
of inheritance of the markers in the family, to identify
whether any sibling of the index patient shared both set
of haplotypes to identify the individual in a preclinical
stage of WD. Theoretically, predictive value for diagnosis
using any one of the three multi-allelic markers used
would be equally good. Additional marker analyses were
done for reproducibility and confidence in the predictive
diagnosis. Also, since the distance of the flanking markers
vary from 917 to 375 kb from WD locus, one has to take
note of the rare but real possibility of recombination
between the marker and WD loci. The reported number
of crossover for the most distant marker D13S314 (917
kb upstream from ATP7B) is1 in 68 meosis14. We also
observed one crossover in 68 meosis. To prevent such
diagnostic error, the diagnostic determination was  based
on the haplotype constructed using all three chosen
markers in the families (Fig. 2).
In the first family (Fig. 2A), the index patient had
three younger sisters including a pair of non-identical
twin with no one having any obvious sign of clinical
abnormality. By haplotype analysis it was revealed that
both the haplotypes ( 147-163-148 and 147- 185 - 150)
of the patient (Fig. 2A, II-1) were shared by one of the
twin sisters (Fig. 2A, II-4) and was thus predicted to
harbor both the mutated copies of the ATP7B present in
the index patient. Between two other sisters detected to
be carrier, the older one (Fig. 2A, II-2) inherited the
mutant chromosome from her mother and the younger
one (Fig. 2A, II-3) inherited the mutant chromosome
from her father.
In the second family, between two brothers of the
patient (Fig. 2B II-1) who were phenotypically normal,
4 yr old younger one (II-3) shared the same pair of
haplotypes (141- 132- 142 and 141- 134- 142) with his
WD affected brother, and is under observation. The other
sibling, II-2 inherited a mutant chromosome (141- 134-
142) from his mother and the normal chromosome
(143- 175- 150) from his father and hence was diagnosed
as a carrier for WD.
In the third family (Fig. 2C), among two younger
sisters of the patient one (12 yr old; II-2) shared the
same genetic materials (151- 157- 150 and 151- 181-
150) around WD locus as her affected brother. Though
she showed no immediate symptoms of WD, she is under
regular observation. The other sister (Fig. 2C, II-3)
inherited both  normal copies of the gene (ATP7B) from
the parents as evident from the haplotypes (147- 169-
150 and 147 - 181- 148).
In the fourth family, the younger brother (11 yr old;
Fig. 2D; II-2) of the index patient had identical haplotypes
(149-179-150 and 139-181-150) as the patient (Fig. 2B,
II-1). In this case, however, the mother (Fig. 2D 1-2) of
the patient was homozygous (139, 139) for the D13S314
marker, which meant that the haplotype 139-181-150 in
the younger son (Fig. 2D, II-2) could be a recombinant,
and might not carry the mutation at the WD locus.
Identification of heterozygosity of the marker (D13S301)
located in between D13S314 and WD locus (Fig. 1,
panel A), which could not be amplified by PCR, might
have resolved the issue. The suspected boy in this family
showed no clinically overt neurological abnormality
though a low normal serum ceruloplasmin was observed.
One of the twin sisters of the first family having
mutated copies of the ATP7B presented after a gap of
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2 yr with prominent abdomen, occasional blackening, loss
of weight and failure to concentrate on her studies and
remember things. She had minimal neurological
abnormalities in the form of tremor and dysarthria; her
liver and spleen were enlarged with the presence of
abdominal fluid. Laboratory investigations revealed a
picture of hepatitis and copper overload confirming it to
be Wilson disease. This patient responded well by
treatment with penicillamine.
In the four cases described, DNA analysis was very
useful for early diagnosis of  the presymptomatic siblings
of WD patients that would have remained undetected
without the molecular diagnosis, thus helping the
clinicians to prevent this crippling disease by timely
medical intervention. The PCR-based diagnostic test can
be performed at any age including in feto .To reduce the
cost of the diagnostic test, one could use only D13S133-
a complex repeat (GA14GT17) and most heterozygous
among the 3 markers analyzed. Identification and use of
markers proximal to or within the WD locus, including
intragenic single nucleotide polymorphism (SNP) in the
ATP7B, would allay any confusion related to the potential
occurrence of recombination of the distant markers.
In this study, the younger siblings of the probands
identified as presymptomatic for WD had the opportunity
for appropriate therapeutic intervention prior to the onset
of the disease. Without the genetic study, their
predisposition for the disease would have remained
unnoticed, till they manifested the signs for the disease.
In WD changes in the biochemical parameters in the
blood and urine precede the clinical symptoms1. Hence
a patient attending the clinic with complaints of early
WD symptoms, actually have a modest to high
derangement of biochemical parameters. Thus individuals
identified as presymtomatics by molecular diagnostic
method can be monitored for progression of the disease
by regular checkups of the biochemical parameters for
therapeutic intervention at appropriate time.
At present studies are in progress to identify the
haplotype(s), which are over-represented among WD
affected individuals in the population, as a strategy to
identify the prevalent mutation(s) in the relatively large
(80 kb) ATP7B gene causal to Wilson Disease. Presence
of eight different haplotypes in the four patients suggests
mutational heterogeneity at the WD locus. Two of  these
haplotypes differ in 1-2 repeat units in only one of the
three markers used. It is, thus, possible that some of the
haplotypes might have resulted from same mutant
chromosome by acquiring allelic variation later in one of
the 3 repeat-marker loci by DNA slippage during
replication.
In developing countries like India, where large families
are common occurrence, multiple members of the family
have potential to be affected with inherited disorders.
The negative impacts on health care cost and quality of
life are particularly high for such debilitating neurological
genetic disorder as WD. The molecular diagnostic test
needs to be used for better clinical management of the
potential patients and genetic counseling to the family
harboring the mutant copies of the gene for proper family
planning.
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